Biomarkers of Parkinson's Disease: Difference between revisions
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
== Introduction == | == Introduction == | ||
The | The Biomarkers Definitions Working Group defines biomarkers (biological markers) as ‘‘a measurable indicator of some biological state or condition that is objectively measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.’’<ref>Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.</ref> | ||
== Sub Heading 2 == | == Sub Heading 2 == | ||
Revision as of 07:11, 8 April 2022
Original Editor - Arnold Fredrick D'Souza
Top Contributors - Arnold Fredrick D'Souza, Libby McConnell, Kim Jackson and Lucinda hampton
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (8/04/2022)
Introduction[edit | edit source]
The Biomarkers Definitions Working Group defines biomarkers (biological markers) as ‘‘a measurable indicator of some biological state or condition that is objectively measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.’’[1]
Sub Heading 2[edit | edit source]
Sub Heading 3[edit | edit source]
Resources[edit | edit source]
- bulleted list
- x
or
- numbered list
- x
References[edit | edit source]
- ↑ Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.
